期刊
JOURNAL OF THORACIC ONCOLOGY
卷 3, 期 7, 页码 728-734出版社
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e31817c6b68
关键词
non-small cell lung cancer; paclitaxel poliglumex; PPX; CT-2103; PS 2; toxicity
Background: Patients with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) have limited life expectancies and decreased tolerance for drug-induced toxicities. Current treatment guidelines indicate that PS 2 patients benefit from systemic therapy. Further refinement of treatment in these patients requires reduction of treatment-associated toxicities while maintaining or improving efficacy. Paclitaxel poliglumex (PPX), a macromolecular polymer-drug conjugate of paclitaxel and poly-L-glutamic acid, may enhance the therapeutic index of paclitaxel. Methods: Chemotherapy-naive PS 2 patients with advanced NSCLC randomly received single-agent PPX (175 mg/m(2)) or a comparator (single-agent vinorelbine or gemcitabine). The primary end point of this study was overall survival. Results: Overall survival was similar between treatment arms (hazard ratio [HR] = 0.95; log-rank p = 0.686). Median and 1-year survival were 7.3 months and 26%, respectively, for PPX versus 6.6 months and 26% for the control arm. There was a nonsignificant trend toward improved survival in women in the PPX arm compared with standard single agents (FIR = 0.65; p = 0.069). The most frequent grade 3/4 adverse events in the treatment versus control arm were dyspnea (13% versus 17%, respectively) and fatigue (10% versus 9%). Grade 3/4 neutropenia and anemia were reduced in the PPX arm (2% versus 8% and 3% versus 9%, respectively). Neuropathy, a taxane-specific toxicity, was more common in the PPX arm; grade 3 neuropathy was limited to 3%. Conclusions: Single-agent PPX, dosed at 175 mg/m(2), is active and well tolerated in PS 2 patients with advanced NSCLC. Patients on PPX required fewer red blood cell transfusions, hematopoietic growth factors, opioid analgesics, and clinic visits than patients receiving gemcitabine or vinorelbine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据